描述
Product Specifications
Attribute | Details |
---|---|
Product Name | Silodosin Capsules |
Generic Name | Silodosin |
CAS Number | 160970?54?7 |
Molecular Formula | C??H??F?N?O? |
Molecular Weight | ~495.5?g/mol |
Dosage Form | Oral gelatin capsule |
Strength | 4?mg per capsule |
Pack Size | 4?mg ×?14 capsules ×?2 blisters per box |
Approval Number | China NMPA H20213639 |
Product Code | 86982249000037 |
Manufacturer | Hainan Wanwei Pharmaceutical Co., Ltd. |
Barcode | — (not provided) |
Storage Conditions | Store at 15?25?°C; protect from light |
Intended Use | Laboratory and preclinical research only |
Mechanism of Action
Silodosin is a highly selective ??A?adrenergic receptor antagonist that relaxes prostate, bladder neck, and urethral smooth muscle, enhancing urinary flow. It has a >500?fold selectivity for ??A over ??B receptors, minimizing systemic hypotension sciencedirect.com+15selleckchem.com+15pubmed.ncbi.nlm.nih.gov+15.
Research Applications & Pharmacology
Benign Prostatic Hyperplasia (BPH):
-
Employed in preclinical models to study symptomatic relief via smooth muscle relaxation .
Urological & Cardiovascular Research:
-
Enables exploration of urinary symptomatology with minimal cardiovascular side effects, a desirable profile in cardiovascular-sensitive studies pubmed.ncbi.nlm.nih.gov.
Receptor Pharmacology:
-
Used in vitro and ex vivo assays to evaluate ??A antagonism. Notably, it shows high affinity (Ki ~0.036?nM) and effectively inhibits receptor-mediated contractions across species .
Pharmacokinetics:
-
Orally bioavailable (~32%), protein binding ~96.6%, metabolized via UGT2B7 and CYP3A4, half-life ~13?±?8?h, excreted ~34% unabsorbed renally and ~55% fecally .
Safety Profile & Handling
-
Cardiovascular Effects: Selectivity for ??A minimizes blood pressure changes; no QT prolongation observed .
-
Common Adverse Events: Dizziness, orthostatic hypotension, dry eyes/mouth, diarrhea, headaches, and retrograde ejaculation.
-
Hepatic & Renal Cautions: Dose adjustments recommended in moderate renal impairment; contraindicated in severe renal/liver dysfunction.
-
Drug Interactions: Contraindicated with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) .
-
Handling: Use standard lab PPE, store in a controlled environment, and dispose of per biosafety guidelines.
评价
目前还没有评价